What types of cancers is Ribociclib/Ribociclib suitable for?

Ribociclib is an oral, selective cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor specifically indicated for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. Since being approved by the US FDA in 2017, Riboxiclib has become an important part of the standard treatment combination for HR+/HER2- breast cancer patients. It is usually combined with aromatase inhibitors (such as letrozole) or fulvestrant, and is especially suitable for postmenopausal or premenopausal patients who have suppressed ovarian function. Riboxiclib mainly inhibits CDK4/6 activity and blocks the transition from G1 to S phase of the cell cycle, thereby effectively delaying the proliferation and spread of cancer cells.

Currently, the main indications for reboxiclib include use in combination with an aromatase inhibitor as initial endocrine therapy for the treatment ofwomen with HR+/HER2- advanced or metastatic breast cancer. In addition, it can also be used in combination with fulvestrant for patients with HR+/HER2- advanced breast cancer whose disease has progressed after previous endocrine therapy. Importantly, multiple large-scale international clinical trials (such as the MONALEESA-2, MONALEESA-3 and MONALEESA-7 studies) have confirmed that Riboxiclib can not only significantly prolong progression-free survival (PFS), but also demonstrated overall survival (OS) benefits in multiple studies, bringing new survival hope to patients with HR+/HER2- breast cancer.

Although the current approved indications for Riboxiclib are mainly in the field of breast cancer, there are also ongoing clinical studies in other types of cancer, such asHR+ endometrial cancer and some prostate cancers, to explore the wider application potential of CDK4/6 inhibitors. However, as of now, Riboxil has not been officially approved for indications other than breast cancer.

Reference materials:https://us.kisqali.com/